Results 41 to 50 of about 15,828 (290)

Statistical analysis of the primary outcome in acute stroke trials [PDF]

, 2012
Common outcome scales in acute stroke trials are ordered categorical or pseudocontinuous in structure but most have been analyzed as binary measures. The use of fixed dichotomous analysis of ordered categorical outcomes after stroke (such as the modified
Altman, H., Bath, P.M.W., Bland, M., Hogg, C., Howard, G., Lees, K.R., Saver, J.L., Schellinger, P.D.   +7 more
core   +1 more source

Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial.

Journal of the American Medical Association (JAMA), 2012
CONTEXT Thrombus embolization during percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) is common and results in suboptimal myocardial perfusion and increased infarct size.
G. Stone, A. Maehara, B. Witzenbichler, J. Godlewski, H. Parise, J. Dambrink, A. Ochała, Trevor W Carlton, Ecaterina Cristea, S. Wolff, S. Brener, S. Chowdhary, M. El-omar, T. Neunteufl, D. Metzger, T. Karwoski, J. Dizon, R. Mehran, C. Gibson   +18 more
semanticscholar   +1 more source

The use of combination of fibrinolytic therapy and abciximab in the treatment of the acute myocardial infarction with ST elevation [PDF]

Vojnosanitetski Pregled, 2002
Background. According to current knowledge, the best way to treat the acute myocardial infarction with ST elevation is primary transluminal coronary angioplasty, which can be performed only in the best equipped tertiary cardiology centers.
Gligić Branko, Dinčić Dragan, Obradović Slobodan, Marković Milić, Orozović Vjekoslav   +4 more
doaj   +1 more source

Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry

BMC Cardiovascular Disorders, 2017
Background Thrombolysis is still used when primary angioplasty is delayed for a long time, but 25%–30% of patients require rescue angioplasty (RA). There are no established recommendations for antithrombotic management in RA.
José M. De la Torre Hernández, Mario Sadaba Sagredo, Miren Telleria Arrieta, Federico Gimeno de Carlos, Elena Sanchez Lacuesta, Juan A. Bullones Ramírez, Javier Pineda Rocamora, Victoria Martin Yuste, Tamara Garcia Camarero, Mariano Larman, Jose R. Rumoroso   +10 more
doaj   +1 more source

Effect of Abciximab Therapy in Patients Undergoing Coronary Angioplasty for Acute ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock.

Circulation Journal, 2015
BACKGROUND The effect of abciximab on survival in patients with ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS) undergoing primary percutaneous coronary intervention (PCI) is not clear.
F. De Felice, F. Tomassini, R. Fiorilli, A. Gagnor, A. Parma, E. Cerrato, C. Musto, M. Nazzaro, F. Varbella, R. Violini   +9 more
semanticscholar   +1 more source

Intracoronary abciximab in STEMI using local drug delivery catheter – Single center experience

Indian Heart Journal, 2013
Background: Despite restoration of epicardial flow during primary PCI in STEMI, microvascular obstruction may persist as a result of both atheromatous and thrombotic embolization and vasospasm.
G. Sengottuvelu, V. Ravi Sekar
doaj   +1 more source

Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab: design and rationale of the High Intensity Transient Signals ReoPro (HITS-RP) study

Cardiovascular Ultrasound, 2012
Background Embolization of atherosclerotic debris from the rupture of a vulnerable atherosclerotic plaque occurs iatrogenically during percutaneous coronary interventions (PCI) and can induce myocardial necrosis.
Kretzschmar Daniel, Jung Christian, Otto Sylvia, Utschig Stephan, Hartmann Michael, Lehmann Thomas, Yilmaz Atilla, Pörner Tudor C, Figulla Hans R, Ferrari Markus   +9 more
doaj   +1 more source

Abciximab-induced delayed profound thrombocytopaenia [PDF]

BMJ Case Reports, 2017
Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy. We present a case of a young woman who initially received abciximab infusion for undergoing percutaneous coronary intervention of left anterior descending artery and was ...
Jbara, Manar, Bhogal, Sukhdeep, Bajaj, Kailash, Chhabra, Lovely   +3 more
openaire   +4 more sources

P2Y12 Receptor Blockade Augments Glycoprotein IIb‐IIIa Antagonist Inhibition of Platelet Activation, Aggregation, and Procoagulant Activity [PDF]

, 2014
Background: New antiplatelet agents that provide greater, more consistent inhibition of the platelet ADP receptor P2Y12 may be used in combination with glycoprotein (GP) IIb‐IIIa antagonists, but their combined effect on platelet function and ...
Barnard, Marc R., Berny‐Lang, Michelle A., Frelinger, Andrew L., Jakubowski, Joseph A., Michelson, Alan D., Sugidachi, Atsuhiro   +5 more
core   +1 more source

Allergic reaction to abciximab with atypical manifestations

Journal of the Saudi Heart Association, 2011
Abciximab (ReoPro, Eli Lilly and Company, Indianapolis, Indiana) is an intravenous agent that had been approved for treatment of acute coronary syndrome undergoing coronary interventions. It is a chimeric monoclonal antibody fragment that binds to the glycoprotein IIb/IIIa receptor with a potential for the development of an immune response to variable ...
Moheeb A. Abdullah, Abdulrahman Almoghairi   +1 more
openaire   +3 more sources